Oxford Biomedica PLC Licence & Supply Agreement with New Partner (5150Y)
September 07 2022 - 1:00AM
UK Regulatory
TIDMOXB
RNS Number : 5150Y
Oxford Biomedica PLC
07 September 2022
Oxford Biomedica signs Licence & Supply Agreement with new
partner for LentiVector(R) platform for late-stage clinical
programme
Oxford, UK - 7 September 2022: Oxford Biomedica plc (LSE:OXB)
("Oxford Biomedica" or "the Company"), a leading gene and cell
therapy group, today announces that it has signed a new Licence and
Supply Agreement ("LSA") with an undisclosed US-based late-stage
cell and gene therapy company. The LSA grants the new partner a
non-exclusive licence to utilise Oxford Biomedica's LentiVector(R)
platform for its application in their lead programme, a cell-based
therapy targeting a rare indication, putting into place a five-year
clinical supply arrangement.
Under the terms of the LSA, Oxford Biomedica will receive an
undisclosed upfront payment, as well as additional payments related
to the development and manufacturing of lentiviral vectors for use
in clinical trials. The Company will also receive certain
development and regulatory milestone payments and an undisclosed
royalty on the net sales of drug product sold that utilises Oxford
Biomedica's LentiVector(R) platform.
Dr. Roch Doliveux, Chair and Interim CEO of Oxford Biomedica,
commented: "This partnership further demonstrates Oxford
Biomedica's world leadership in the delivery of viral vectors for
cell and gene therapies and the momentum we are building, with this
being the fifth new or expanded customer partnership we have
announced this year. We look forward to continuing to build upon
our position as a partner of choice to deliver life-saving cell and
gene therapies to patients."
-Ends-
Enquiries:
Oxford Biomedica plc: T: +44 (0)1865 783 000 / E: ir@oxb.com
Stuart Paynter, Chief Financial Officer
Sophia Bolhassan, VP, Corporate Affairs & Investor
Relations
Consilium Strategic Communications:
T: +44 (0)20 3709 5700 / E:
oxfordbiomedica@consilium-comms.com
Mary-Jane Elliott / Matthew Neal / Matthew Cole
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is an innovative leading viral vector
specialist focused on delivering life changing therapies to
patients.
Oxford Biomedica plc and its subsidiaries (the Group) work
across key viral vector delivery systems including those based on
lentivirus, adeno-associated virus (AAV) and adenovirus, providing
innovative solutions to cell and gene therapy biotechnology and
biopharma companies for their process development, analytical
development and manufacturing needs. Oxford Biomedica has built a
sector leading lentiviral vector delivery system, LentiVector(R)
platform, which the Group leverages to develop product candidates
in-house, before seeking partners to take the products into
clinical trials.
Oxford Biomedica is based across several locations and
headquartered in Oxfordshire, UK. In early 2022, the Group
established Oxford Biomedica Solutions, a new US based subsidiary
AAV manufacturing and innovation business, based near Boston,
US.
Oxford Biomedica employs more than 940 people. Further
information is available at www.oxb.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCSSUESMEESEFU
(END) Dow Jones Newswires
September 07, 2022 02:00 ET (06:00 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024